Weaponizing CRISPR/Cas9 for selective elimination of cells with an aberrant genome
RNA-seq profiling of HeLa GFP cells treated with a Cas9 bearing either a scramble or a GFP guide to study the activation of inflammatory pathways 3 days after Cas9 delivery